| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0166-0934(02)00059-9 |
| P698 | PubMed publication ID | 12088824 |
| P2093 | author name string | Jörg-Peter Kleim | |
| Catherine V Gale | |||
| Laurence H Robinson | |||
| P2860 | cites work | Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds | Q28339318 |
| In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632 | Q28344594 | ||
| Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. | Q28378727 | ||
| Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors | Q28378860 | ||
| Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. | Q30416612 | ||
| Proline residues in human immunodeficiency virus type 1 p6(Gag) exert a cell type-dependent effect on viral replication and virion incorporation of Pol proteins. | Q33813648 | ||
| Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. | Q33838311 | ||
| A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1 | Q33979107 | ||
| Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5) | Q33981401 | ||
| PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates | Q35100239 | ||
| Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients | Q39580564 | ||
| Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase n | Q39653073 | ||
| Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants | Q40794846 | ||
| Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs. | Q43606007 | ||
| Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. | Q43797586 | ||
| Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies | Q45746500 | ||
| PCR-mediated recombination: a general method applied to construct chimeric infectious molecular clones of plasma-derived HIV-1 RNA. | Q45856095 | ||
| HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays | Q74213231 | ||
| Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors | Q74220146 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 147-160 | |
| P577 | publication date | 2002-07-01 | |
| P1433 | published in | Journal of Virological Methods | Q15749961 |
| P1476 | title | Inclusion of full length human immunodeficiency virus type 1 (HIV-1) gag sequences in viral recombinants applied to drug susceptibility phenotyping | |
| P478 | volume | 104 |
| Q41400528 | A single-loop recombinant pseudotyped-virus-based assay to detect HIV-1 phenotypic resistance |
| Q34290545 | Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy |
| Q39749215 | In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection |
| Q34083261 | Interplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02_AG |
| Q40120304 | Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency |
| Q40380034 | Mutations in both env and gag genes are required for HIV-1 resistance to the polysulfonic dendrimer SPL2923, as corroborated by chimeric virus technology |
| Q42148219 | Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of ant |
| Q36414162 | Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates. |
Search more.